Engineered immune cells take on deadly brain tumors

NCT ID NCT06355908

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a personalized cell therapy called IL13Rα2 CAR-T for people with recurrent grade 4 glioma, an aggressive brain cancer. The treatment involves collecting a patient's immune cells, engineering them to target a protein on tumor cells, and infusing them back into the brain. The main goal is to check safety, but researchers will also look for signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IL13Rα2-targeted CAR-T cells
What this could lead to
If successful, this could point toward a new treatment option for recurrent grade 4 glioma, a brain cancer with few effective therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so it may not show clear benefit. The treatment is suspended, and there are risks like brain inflammation or other serious side effects from CAR-T therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tiantan Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.